Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | PGR | P06401 | 2/20 | 0.30 |
| ▸ | PPARG | P37231 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22922703 | 1.00 | LMNA (0.37) | LMNAGAAHPGDHTTSMN1; SMN2 | |
| SCHEMBL21436580 | 1.00 | LMNA (0.37) | LMNAGAAHPGDHTTSMN1; SMN2 | |
| SCHEMBL21436474 | 0.83 | LMNA (0.38) | LMNAGAAHPGDHTTSMN1; SMN2 | |
| SCHEMBL21436471 | 0.83 | LMNA (0.38) | LMNAGAAHPGDHTTSMN1; SMN2 | |
| SCHEMBL21436494 | 0.77 | HPGD (0.41) | LMNAHPGDHTTALDH1A1CA2 | |
| SCHEMBL22922704 | 0.77 | HPGD (0.41) | LMNAHPGDHTTALDH1A1CA2 | |
| SCHEMBL21436493 | 0.77 | HPGD (0.41) | LMNAHPGDHTTALDH1A1CA2 | |
| SCHEMBL573731 | 0.68 | HPGD (0.43) | LMNAGAAHPGDHTTSMN1; SMN2 | |
| SCHEMBL8260574 | 0.67 | LMNA (0.43) | LMNAGAAHPGDSMN1; SMN2BCAT1 | |
| SCHEMBL21453464 | 0.66 | ALDH1A1 (0.42) | LMNAGAAHTTSMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3774763-A1 | BUMETANIDE DERIVATIVES FOR THE THERAPY OF HYPERHIDROSIS | ZILENTIN AG (CH) | 2021-02-17 | — | — | EP | disclosed |
| US-20210022978-A1 | BUMETANIDE DERIVATIVES FOR THE THERAPY OF HYPERHIDROSIS | Zilentin AG (CH) | 2021-01-28 | — | — | US | disclosed |
| WO-2019193159-A1 | BUMETANIDE DERIVATIVES FOR THE THERAPY OF HYPERHIDROSIS | Universität Wien (AT) | 2019-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210022978-A1 | BUMETANIDE DERIVATIVES FOR THE THERAPY OF HYPERHIDROSIS | SLC9A1, SLC9A3, SLC5A1 | LMNA 4608/4885GAA 649/4885HPGD 524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.